查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1472276

全球生物標記物市場：按類型、應用和服務 - 機會分析和產業預測，2024-2033 年

Biomarkers Market By Type, By Application, By Services : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 347 Pages | 商品交期: 2-3個工作天內

價格

預計2023年全球生物標記市場規模將達464億美元，2024年至2033年複合年成長率為11.2%，2033年將達1342億美元。

生物標記市場-IMG1

生物標記是可測量的指標，提供有關生物過程、健康狀況和治療性介入反應的重要資訊。這些標記物存在於各種體液、組織或影像資料中，在疾病診斷、預後和監測中發揮重要作用。它作為一種客觀、可量化的指標，幫助臨床醫生評估疾病的存在、嚴重程度和進展。生物標記包括廣泛的蛋白質、核酸、代謝物和成像參數，反映了生物系統的多樣性。

由於慢性病盛行率上升以及藥物開發過程中生物標記物的採用率較高，預計生物標記物市場將在預測期內顯著成長。

慢性病的增加已成為推動生物標記市場成長的關鍵因素。近年來，心血管疾病、癌症、糖尿病和神經退化性疾病的盛行率在全球範圍內急劇上升。例如，世界衛生組織（WHO）2024年報告估計，到2050年將有超過3500萬名新癌症患者被診斷出來。這種激增是由多種因素造成的，包括久坐的生活方式、不健康的飲食和人口老化。隨著慢性病繼續給醫療保健系統帶來沉重負擔，早期準確的診斷對於有效的疾病管理變得越來越重要。

生物標記是生物過程或狀況的可測量指標，透過提供對個體生理狀態的寶貴見解，在疾病診斷中發揮重要作用。生物標記有助於早期檢測、風險評估和疾病進展監測，從而實現及時干預和個人化治療策略。例如，美國生技公司 Guardant Health 提供 Guardant360 CDx 測試。 Guardant360 CDx 測試已獲得 FDA核准作為所有固體癌的完整基因組測試。該測試可在基本血液檢查後 7 天內提供全面的基因組測試結果，幫助醫生做出明智的治療方法選擇。此外，基因組學、蛋白質組學和代謝體學的技術進步擴大了臨床使用的生物標記的範圍，並提高了其診斷各種疾病的有效性。因此，慢性病盛行率的增加預計將推動市場成長。

生物標記在藥物開發過程中的快速採用是推動生物標記市場成長的關鍵因素。生物標記被定義為生物過程或治療性介入的可測量指標，已成為藥物開發過程中的重要工具。生物標記徹底改變了製藥公司發現和開發藥物的方式，因為它們可以提供有關生物體生理和分子生物學狀態的準確、即時資訊。生物標記提供了一種客觀評估新藥從臨床前測試到臨床試驗各個階段的功效、安全性和潛在副作用的方法。這可以加快藥物開發時間並增加成功的可能性。例如，根據國家醫學圖書館 2020 年的一份報告，生物標記廣泛應用於藥物發現和開發的各個階段。生物標記的使用有可能使藥物發現、開發和核准過程更有效率。因此，在藥物發現和開發過程中擴大採用生物標記預計將顯著促進市場成長。

然而，資料安全和隱私問題已成為限制市場成長的主要問題。生命科學產業嚴重依賴收集、儲存和分析大量敏感資料，包括病患記錄、臨床試驗資訊和基因組資料。隨著醫療保健流程變得更加數位化並採​​用雲端運算和巨量資料分析等尖端技術，資料外洩和未授權存取的風險正在增加。因此，對資料安全和隱私的擔憂預計將抑制市場成長。

此外，高昂的開發成本也可能抑制市場成長。生物標記的發現和檢驗需要大量的研究和開發成本。生物標記開發和檢驗的高成本對生物標記的採用產生負面影響，特別是在中小型企業中。

生物標記市場按類型、應用、服務和地區進行細分。依類型分為功效生物標記、安全生物標記和檢驗生物標記。依應用分為風險評估、分子診斷開發、疾病診斷、藥物發現/市場開拓、製劑、法醫學使用等。

依服務分類，可分為藥物/樣品製備、分析開發、生物標記驗證/測試和其他服務。按地區：北美（美國、加拿大、墨西哥）、歐洲（法國、德國、義大利、西班牙、英國、英國其他地區）、亞太地區（中國、日本、印度、韓國、澳洲、亞太地區其他地區） ），太平洋地區的亞洲分析（巴西、日本、印度、韓國、澳洲、阿拉伯半島和亞太其他地區）。

相關人員的主要利益

  • 該報告定量提供了2023年至2033年生物標記市場分析的細分市場、當前趨勢、估計/趨勢分析和動態，並確定了生物標記市場有前景的市場機會。
  • 我們提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。
  • 波特的五力分析強調買家和供應商幫助相關人員做出利潤驅動的商業決策並加強供應商-買家網路的力量。
  • 對生物標記市場細分的詳細分析有助於識別市場機會。
  • 我們根據每個地區的主要國家對全球市場的收益貢獻繪製了地圖。
  • 市場參與者定位有助於基準化分析，並提供對市場參與者當前地位的清晰了解。
  • 該報告包括對區域和全球生物標記市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

該報告可以客製化。

  • 根據客戶興趣加入公司簡介
  • 按國家或地區分類的附加分析、市場規模和預測
  • 十字交叉細分市場分析、市場規模與預測
  • 公司簡介的擴充列表
  • 歷史市場資料
  • 主要參與者的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）
  • 全球/區域/國家層級參與者的市場佔有率分析
  • SWOT分析

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 生物標記在藥物發現和開發過程中的採用率很高。
      • 慢性病快速增加
      • 在法醫學分析中更多地採用生物標記物。
    • 抑制因素
      • 生物標誌開發成本高
    • 機會
      • 私人組織與政府機構合作開發生物標記。

第4章生物標記市場：依類型

  • 概述
  • 功效生物標記
  • 安全生物標記
  • 驗證生物標記

第5章生物標記市場：依應用分類

  • 概述
  • 風險評估
  • 分子診斷學的發展
  • 疾病診斷
  • 藥物發現和藥物開發
  • 藥物製劑
  • 法醫學應用
  • 其他

第6章生物標記市場：依服務分類

  • 概述
  • 樣品製備
  • 檢測開發
  • 生物標記驗證/測試
  • 其他服務

第7章生物標記市場：按地區

  • 概述
  • 北美洲
    • 北美藥物發現和市場開拓生物標記市場：按類型
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲藥物發現和市場開拓生物標記市場：按類型
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 亞太地區藥物發現和市場開拓生物標記市場：按類型
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他亞太地區
  • 拉丁美洲/中東/非洲
    • 拉丁美洲、中東和非洲的藥物發現和市場開拓生物標記市場：按類型
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他拉丁美洲/中東/非洲

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2023年主要企業定位

第9章 公司簡介

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories, Inc.
  • GE Healthcare
  • Siemens AG
  • Thermo Fisher Scientific
  • Qiagen NV
  • Merck KGaA
  • F. Hoffmann-La Roche AG
  • Revvity, Inc.
Product Code: A00021

The global biomarkers market size was valued at $46.4 billion in 2023, and is projected to reach $134.2 billion by 2033, growing at a CAGR of 11.2% from 2024 to 2033.

Biomarkers Market - IMG1

Biomarkers are measurable indicators that provide essential information about biological processes, health conditions, or responses to therapeutic interventions. These markers, found in various bodily fluids, tissues, or even imaging data, play a crucial role in diagnostics, prognosis, and monitoring of diseases. They serve as objectifiable and quantifiable measures, aiding clinicians in assessing the presence, severity, and progression of illnesses. Biomarkers cover a broad spectrum, including proteins, nucleic acids, metabolites, and imaging parameters, reflecting the diverse nature of biological systems.

The biomarkers market is expected to register significant growth during the forecast period owing to a rise in incidence of chronic diseases and high adoption of the biomarkers in the drug development process.

The rise in incidence of chronic diseases has emerged as a pivotal driver propelling the growth of the biomarkers market. In recent years, there has been a noteworthy surge in the prevalence of conditions such as cardiovascular diseases, cancer, diabetes, and neurodegenerative disorders globally. For instance, according to the 2024 report by World Health Organization, it was estimated that over 35 million new cancer cases are expected to be diagnosed in 2050. This surge is attributed to several factors, such as sedentary lifestyles, unhealthy dietary habits, and an aging population. As chronic diseases continue to impose a substantial burden on healthcare systems, there is an increase in emphasis on early and accurate diagnosis for effective disease management.

Biomarkers, which are measurable indicators of biological processes or conditions, play a crucial role in disease diagnosis by providing valuable insights into the physiological state of an individual. Biomarkers facilitate early detection, risk assessment, and monitoring of disease progression, enabling timely intervention and personalized treatment strategies. For instance, Guardant Health, an American biotechnology firm, provides Guardant360 CDx test. Guardant360 CDx test is FDA-approved for complete genomic testing for all solid cancers. The test delivers comprehensive genomic results within 7 days of a basic blood test, helping doctors make informed treatment choices. Furthermore, technological advancements in genomics, proteomics, and metabolomics have broadened the range of biomarkers for clinical use, improving their effectiveness in diagnosis of various diseases. Thus, the rise in the incidence of chronic diseases is expected to drive the growth of the market.

The surge in adoption of biomarkers in the drug development process stands as a pivotal driver propelling the growth of the biomarkers market. Biomarkers, defined as measurable indicators of biological processes or responses to therapeutic interventions, have become indispensable tools in the drug development process. The ability of biomarkers to provide precise and real-time information about the physiological and molecular status of an organism has revolutionized the way pharmaceutical companies approach drug discovery and development. Biomarkers offer a means to objectively assess the efficacy, safety, and potential adverse effects of new drugs at various stages, from preclinical studies to clinical trials. This expedites the drug development timeline and enhances the probability of successful outcomes. For instance, according to the 2020 report by the National Library of Medicine, biomarkers are widely used at every stage of drug discovery and development. Utilization of biomarkers has a potential to make drug discovery, development, and approval processes more efficient. Thus, the rise in adoption of biomarkers in the drug discovery and development procedure is expected to contribute significantly to the growth of the market.

However, data security and privacy concerns have emerged as major concerns that restrain the growth of the market. The life sciences industry relies heavily on the collection, storage, and analysis of vast amounts of sensitive and confidential data, including patient records, clinical trial information, and genomic data. With the increase in digitization of healthcare processes and the adoption of advanced technologies, such as cloud computing and big data analytics, the risk of data breaches and unauthorized access has escalated. Thus, data security and privacy concerns are expected to restrain the growth of the market.

In addition, high development costs might restrain the growth of the market. The discovery and validation of biomarkers involve significant R&D costs. The high cost of developing and validating biomarkers negatively impacts the adoption of the biomarkers particularly in smaller companies.

The biomarkers market is segmented on the basis of type, application, service, and region. By type, the market is divided into efficacy biomarkers, safety biomarkers, and validation biomarkers. By application, the market is divided into risk assessment, development of molecular diagnostic, disease diagnosis, drug discovery & development, drug formulation, forensic application, and others.

By service, it is classified into pharmaceutical & sample preparation, assay development, biomarker validation & testing, and other services. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (France, Germany, Italy, Spain, UK, and rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, rest of LAMEA)

The major players profiled in the report are GE Healthcare, Abbott Laboratories, Inc., Bio-Rad Laboratories, Epistem Ltd., Eisai Co. Ltd., Roche Diagnostics Limited, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Aushon Biosystem, and Siemens AG.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biomarkers market analysis from 2023 to 2033 to identify the prevailing biomarkers market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the biomarkers market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global biomarkers market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • Market share analysis of players at global/region/country level
  • SWOT Analysis

Key Market Segments

By Type

  • Safety Biomarkers
  • Validation Biomarkers
  • Efficacy Biomarkers

By Application

  • Risk Assessment
  • Development of Molecular Diagnostic
  • Disease Diagnosis
  • Drug Discovery and Development
    • Type
    • Clinical Trial - Pre Clinical Phase and Phase 1
    • Clinical Trial Phase 2
    • Clinical Trial Phase 3
    • Clinical Trial Commercial Phase
  • Drug Formulation
  • Forensic Application
  • Others

By Services

  • Sample Preparation
  • Assay Development
  • Biomarker Validation and Testing
  • Other Services

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Bio-Rad Laboratories, Inc.
    • Thermo Fisher Scientific
    • Qiagen N.V
    • F. Hoffmann-La Roche AG
    • GE Healthcare
    • Revvity, Inc.
    • Abbott Laboratories
    • Siemens AG
    • Merck KGaA
    • Agilent Technologies Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. High adoption of biomarkers in drug discovery and development process.
      • 3.4.1.2. Surge in prevalence of chronic diseases.
      • 3.4.1.3. Rise in adoption of biomarkers in forensic analysis.
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of development of biomarkers.
    • 3.4.3. Opportunities
      • 3.4.3.1. Collaborative efforts by private and government organizations for development of biomarkers.

CHAPTER 4: BIOMARKERS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Efficacy Biomarkers
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Safety Biomarkers
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Validation Biomarkers
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: BIOMARKERS MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Risk Assessment
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Development of Molecular Diagnostic
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Disease Diagnosis
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Drug Discovery and Development
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
    • 5.5.4. Drug Discovery and Development Biomarkers Market by Type
      • 5.5.4.1. Clinical Trial - Pre Clinical Phase and Phase 1 Market size and forecast, by region
      • 5.5.4.2. Clinical Trial Phase 2 Market size and forecast, by region
      • 5.5.4.3. Clinical Trial Phase 3 Market size and forecast, by region
      • 5.5.4.4. Clinical Trial Commercial Phase Market size and forecast, by region
  • 5.6. Drug Formulation
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Forensic Application
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country
  • 5.8. Others
    • 5.8.1. Key market trends, growth factors and opportunities
    • 5.8.2. Market size and forecast, by region
    • 5.8.3. Market share analysis by country

CHAPTER 6: BIOMARKERS MARKET, BY SERVICES

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Sample Preparation
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Assay Development
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Biomarker Validation and Testing
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Other Services
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country

CHAPTER 7: BIOMARKERS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Application
      • 7.2.3.1. North America Drug Discovery and Development Biomarkers Market by Type
    • 7.2.4. Market size and forecast, by Services
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Type
      • 7.2.5.1.2. Market size and forecast, by Application
      • 7.2.5.1.3. Market size and forecast, by Services
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Type
      • 7.2.5.2.2. Market size and forecast, by Application
      • 7.2.5.2.3. Market size and forecast, by Services
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Type
      • 7.2.5.3.2. Market size and forecast, by Application
      • 7.2.5.3.3. Market size and forecast, by Services
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Application
      • 7.3.3.1. Europe Drug Discovery and Development Biomarkers Market by Type
    • 7.3.4. Market size and forecast, by Services
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. UK
      • 7.3.5.1.1. Market size and forecast, by Type
      • 7.3.5.1.2. Market size and forecast, by Application
      • 7.3.5.1.3. Market size and forecast, by Services
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Type
      • 7.3.5.2.2. Market size and forecast, by Application
      • 7.3.5.2.3. Market size and forecast, by Services
      • 7.3.5.3. Germany
      • 7.3.5.3.1. Market size and forecast, by Type
      • 7.3.5.3.2. Market size and forecast, by Application
      • 7.3.5.3.3. Market size and forecast, by Services
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Type
      • 7.3.5.4.2. Market size and forecast, by Application
      • 7.3.5.4.3. Market size and forecast, by Services
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Type
      • 7.3.5.5.2. Market size and forecast, by Application
      • 7.3.5.5.3. Market size and forecast, by Services
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Type
      • 7.3.5.6.2. Market size and forecast, by Application
      • 7.3.5.6.3. Market size and forecast, by Services
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Application
      • 7.4.3.1. Asia-Pacific Drug Discovery and Development Biomarkers Market by Type
    • 7.4.4. Market size and forecast, by Services
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Type
      • 7.4.5.1.2. Market size and forecast, by Application
      • 7.4.5.1.3. Market size and forecast, by Services
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Type
      • 7.4.5.2.2. Market size and forecast, by Application
      • 7.4.5.2.3. Market size and forecast, by Services
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Type
      • 7.4.5.3.2. Market size and forecast, by Application
      • 7.4.5.3.3. Market size and forecast, by Services
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Type
      • 7.4.5.4.2. Market size and forecast, by Application
      • 7.4.5.4.3. Market size and forecast, by Services
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Type
      • 7.4.5.5.2. Market size and forecast, by Application
      • 7.4.5.5.3. Market size and forecast, by Services
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Type
      • 7.4.5.6.2. Market size and forecast, by Application
      • 7.4.5.6.3. Market size and forecast, by Services
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Application
      • 7.5.3.1. LAMEA Drug Discovery and Development Biomarkers Market by Type
    • 7.5.4. Market size and forecast, by Services
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Type
      • 7.5.5.1.2. Market size and forecast, by Application
      • 7.5.5.1.3. Market size and forecast, by Services
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Type
      • 7.5.5.2.2. Market size and forecast, by Application
      • 7.5.5.2.3. Market size and forecast, by Services
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Type
      • 7.5.5.3.2. Market size and forecast, by Application
      • 7.5.5.3.3. Market size and forecast, by Services
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Type
      • 7.5.5.4.2. Market size and forecast, by Application
      • 7.5.5.4.3. Market size and forecast, by Services

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Abbott Laboratories
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Agilent Technologies Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Bio-Rad Laboratories, Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. GE Healthcare
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Siemens AG
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Thermo Fisher Scientific
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Qiagen N.V
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Merck KGaA
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. F. Hoffmann-La Roche AG
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Revvity, Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 02. BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 03. BIOMARKERS MARKET FOR SAFETY BIOMARKERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 04. BIOMARKERS MARKET FOR VALIDATION BIOMARKERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 05. GLOBAL BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 06. BIOMARKERS MARKET FOR RISK ASSESSMENT, BY REGION, 2023-2033 ($MILLION)
  • TABLE 07. BIOMARKERS MARKET FOR DEVELOPMENT OF MOLECULAR DIAGNOSTIC, BY REGION, 2023-2033 ($MILLION)
  • TABLE 08. BIOMARKERS MARKET FOR DISEASE DIAGNOSIS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 09. BIOMARKERS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2023-2033 ($MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY AND DEVELOPMENT BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 11. BIOMARKERS MARKET FOR CLINICAL TRIAL - PRE CLINICAL PHASE AND PHASE 1, BY REGION, 2023-2033 ($MILLION)
  • TABLE 12. BIOMARKERS MARKET FOR CLINICAL TRIAL PHASE 2, BY REGION, 2023-2033 ($MILLION)
  • TABLE 13. BIOMARKERS MARKET FOR CLINICAL TRIAL PHASE 3, BY REGION, 2023-2033 ($MILLION)
  • TABLE 14. BIOMARKERS MARKET FOR CLINICAL TRIAL COMMERCIAL PHASE, BY REGION, 2023-2033 ($MILLION)
  • TABLE 15. BIOMARKERS MARKET FOR DRUG FORMULATION, BY REGION, 2023-2033 ($MILLION)
  • TABLE 16. BIOMARKERS MARKET FOR FORENSIC APPLICATION, BY REGION, 2023-2033 ($MILLION)
  • TABLE 17. BIOMARKERS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 18. GLOBAL BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 19. BIOMARKERS MARKET FOR SAMPLE PREPARATION, BY REGION, 2023-2033 ($MILLION)
  • TABLE 20. BIOMARKERS MARKET FOR ASSAY DEVELOPMENT, BY REGION, 2023-2033 ($MILLION)
  • TABLE 21. BIOMARKERS MARKET FOR BIOMARKER VALIDATION AND TESTING, BY REGION, 2023-2033 ($MILLION)
  • TABLE 22. BIOMARKERS MARKET FOR OTHER SERVICES, BY REGION, 2023-2033 ($MILLION)
  • TABLE 23. BIOMARKERS MARKET, BY REGION, 2023-2033 ($MILLION)
  • TABLE 24. NORTH AMERICA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 25. NORTH AMERICA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 26. NORTH AMERICA DRUG DISCOVERY AND DEVELOPMENT BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 27. NORTH AMERICA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 28. NORTH AMERICA BIOMARKERS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 29. U.S. BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 30. U.S. BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 31. U.S. BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 32. CANADA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 33. CANADA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 34. CANADA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 35. MEXICO BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 36. MEXICO BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 37. MEXICO BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 38. EUROPE BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 39. EUROPE BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 40. EUROPE DRUG DISCOVERY AND DEVELOPMENT BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 41. EUROPE BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 42. EUROPE BIOMARKERS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 43. UK BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 44. UK BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 45. UK BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 46. FRANCE BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 47. FRANCE BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 48. FRANCE BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 49. GERMANY BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 50. GERMANY BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 51. GERMANY BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 52. ITALY BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 53. ITALY BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 54. ITALY BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 55. SPAIN BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 56. SPAIN BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 57. SPAIN BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 58. REST OF EUROPE BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 59. REST OF EUROPE BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 60. REST OF EUROPE BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 61. ASIA-PACIFIC BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 62. ASIA-PACIFIC BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 63. ASIA-PACIFIC DRUG DISCOVERY AND DEVELOPMENT BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 64. ASIA-PACIFIC BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 65. ASIA-PACIFIC BIOMARKERS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 66. JAPAN BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 67. JAPAN BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 68. JAPAN BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 69. CHINA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 70. CHINA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 71. CHINA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 72. INDIA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 73. INDIA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 74. INDIA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 75. AUSTRALIA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 76. AUSTRALIA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 77. AUSTRALIA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 78. SOUTH KOREA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 79. SOUTH KOREA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 80. SOUTH KOREA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 81. REST OF ASIA-PACIFIC BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 82. REST OF ASIA-PACIFIC BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 83. REST OF ASIA-PACIFIC BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 84. LAMEA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 85. LAMEA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 86. LAMEA DRUG DISCOVERY AND DEVELOPMENT BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 87. LAMEA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 88. LAMEA BIOMARKERS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 89. BRAZIL BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 90. BRAZIL BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 91. BRAZIL BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 92. SAUDI ARABIA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 93. SAUDI ARABIA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 94. SAUDI ARABIA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 95. SOUTH AFRICA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 96. SOUTH AFRICA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 97. SOUTH AFRICA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 98. REST OF LAMEA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
  • TABLE 99. REST OF LAMEA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
  • TABLE 100. REST OF LAMEA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
  • TABLE 101. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 102. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 103. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 104. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 105. ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 106. AGILENT TECHNOLOGIES INC.: KEY EXECUTIVES
  • TABLE 107. AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT
  • TABLE 108. AGILENT TECHNOLOGIES INC.: PRODUCT SEGMENTS
  • TABLE 109. AGILENT TECHNOLOGIES INC.: PRODUCT PORTFOLIO
  • TABLE 110. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
  • TABLE 111. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
  • TABLE 112. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
  • TABLE 113. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
  • TABLE 114. GE HEALTHCARE: KEY EXECUTIVES
  • TABLE 115. GE HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 116. GE HEALTHCARE: PRODUCT SEGMENTS
  • TABLE 117. GE HEALTHCARE: SERVICE SEGMENTS
  • TABLE 118. GE HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 119. GE HEALTHCARE: KEY STRATERGIES
  • TABLE 120. SIEMENS AG: KEY EXECUTIVES
  • TABLE 121. SIEMENS AG: COMPANY SNAPSHOT
  • TABLE 122. SIEMENS AG: PRODUCT SEGMENTS
  • TABLE 123. SIEMENS AG: PRODUCT PORTFOLIO
  • TABLE 124. SIEMENS AG: KEY STRATERGIES
  • TABLE 125. THERMO FISHER SCIENTIFIC: KEY EXECUTIVES
  • TABLE 126. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 127. THERMO FISHER SCIENTIFIC: PRODUCT SEGMENTS
  • TABLE 128. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 129. THERMO FISHER SCIENTIFIC: KEY STRATERGIES
  • TABLE 130. QIAGEN N.V: KEY EXECUTIVES
  • TABLE 131. QIAGEN N.V: COMPANY SNAPSHOT
  • TABLE 132. QIAGEN N.V: PRODUCT SEGMENTS
  • TABLE 133. QIAGEN N.V: PRODUCT PORTFOLIO
  • TABLE 134. QIAGEN N.V: KEY STRATERGIES
  • TABLE 135. MERCK KGAA: KEY EXECUTIVES
  • TABLE 136. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 137. MERCK KGAA: PRODUCT SEGMENTS
  • TABLE 138. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 139. MERCK KGAA: KEY STRATERGIES
  • TABLE 140. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
  • TABLE 141. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 142. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
  • TABLE 143. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 144. F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
  • TABLE 145. REVVITY, INC.: KEY EXECUTIVES
  • TABLE 146. REVVITY, INC.: COMPANY SNAPSHOT
  • TABLE 147. REVVITY, INC.: PRODUCT SEGMENTS
  • TABLE 148. REVVITY, INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. BIOMARKERS MARKET, 2023-2033
  • FIGURE 02. SEGMENTATION OF BIOMARKERS MARKET,2023-2033
  • FIGURE 03. TOP IMPACTING FACTORS IN BIOMARKERS MARKET (2023 TO 2033)
  • FIGURE 04. TOP INVESTMENT POCKETS IN BIOMARKERS MARKET (2024-2033)
  • FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL BIOMARKERS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. BIOMARKERS MARKET, BY TYPE, 2023 AND 2033(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR SAFETY BIOMARKERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR VALIDATION BIOMARKERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 15. BIOMARKERS MARKET, BY APPLICATION, 2023 AND 2033(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR RISK ASSESSMENT, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR DEVELOPMENT OF MOLECULAR DIAGNOSTIC, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR DISEASE DIAGNOSIS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR DRUG FORMULATION, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR FORENSIC APPLICATION, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 23. BIOMARKERS MARKET, BY SERVICES, 2023 AND 2033(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR SAMPLE PREPARATION, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR ASSAY DEVELOPMENT, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR BIOMARKER VALIDATION AND TESTING, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR OTHER SERVICES, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 28. BIOMARKERS MARKET BY REGION, 2023 AND 2033(%)
  • FIGURE 29. U.S. BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 30. CANADA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 31. MEXICO BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 32. UK BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 33. FRANCE BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 34. GERMANY BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 35. ITALY BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 36. SPAIN BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 37. REST OF EUROPE BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 38. JAPAN BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 39. CHINA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 40. INDIA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 41. AUSTRALIA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 42. SOUTH KOREA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 43. REST OF ASIA-PACIFIC BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 44. BRAZIL BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 45. SAUDI ARABIA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 46. SOUTH AFRICA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 47. REST OF LAMEA BIOMARKERS MARKET, 2023-2033 ($MILLION)
  • FIGURE 48. TOP WINNING STRATEGIES, BY YEAR (2021-2024)
  • FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2024)
  • FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY (2021-2024)
  • FIGURE 51. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 52. COMPETITIVE DASHBOARD
  • FIGURE 53. COMPETITIVE HEATMAP: BIOMARKERS MARKET
  • FIGURE 54. TOP PLAYER POSITIONING, 2023
  • FIGURE 55. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. AGILENT TECHNOLOGIES INC.: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 59. AGILENT TECHNOLOGIES INC.: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 60. AGILENT TECHNOLOGIES INC.: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 61. BIO-RAD LABORATORIES, INC. : NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 63. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. GE HEALTHCARE: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 65. GE HEALTHCARE: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 66. GE HEALTHCARE: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 67. SIEMENS AG: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 68. SIEMENS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 69. SIEMENS AG: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 70. THERMO FISHER SCIENTIFIC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 71. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 72. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 73. QIAGEN N.V: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 74. QIAGEN N.V: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 75. MERCK KGAA: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 76. MERCK KGAA: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 77. MERCK KGAA: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 78. F. HOFFMANN-LA ROCHE AG: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 79. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 80. REVVITY, INC.: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 81. REVVITY, INC.: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 82. REVVITY, INC.: REVENUE SHARE BY REGION, 2023 (%)